1
|
Croxton T, Jonathan E, Suleiman K, Balogun O, Ozumba PJ, Aloyo SM, Nsubuga G, Kamulegeya RE, Newton L, Mukisa J, Kader M, Damaneite V, Nadoma S, Onyemata EJ, Anzaku AA, Nasinghe E, Troyer J, Joubert BR, Beiswanger C, Joloba ML, Mayne E, Abimiku A. Building blocks for better biorepositories in Africa. Genome Med 2023; 15:92. [PMID: 37932809 PMCID: PMC10626646 DOI: 10.1186/s13073-023-01235-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Accepted: 09/19/2023] [Indexed: 11/08/2023] Open
Abstract
BACKGROUND Biorepositories archive and distribute well-characterized biospecimens for research to support the development of medical diagnostics and therapeutics. Knowledge of biobanking and associated practices is incomplete in low- and middle-income countries where disease burden is disproportionately high. In 2011, the African Society of Human Genetics (AfSHG), the National Institutes of Health (NIH), and the Wellcome Trust founded the Human Heredity and Health in Africa (H3Africa) consortium to promote genomic research in Africa and established a network of three biorepositories regionally located in East, West, and Southern Africa to support biomedical research. This manuscript describes the processes established by H3Africa biorepositories to prepare research sites to collect high-quality biospecimens for deposit at H3Africa biorepositories. METHODS The biorepositories harmonized practices between the biorepositories and the research sites. The biorepositories developed guidelines to establish best practices and define biospecimen requirements; standard operating procedures (SOPs) for common processes such as biospecimen collection, processing, storage, transportation, and documentation as references; requirements for minimal associated datasets and formats; and a template material transfer agreements (MTA) to govern biospecimen exchange. The biorepositories also trained and mentored collection sites in relevant biobanking processes and procedures and verified biospecimen deposit processes. Throughout these procedures, the biorepositories followed ethical and legal requirements. RESULTS The 20 research projects deposited 107,982 biospecimens (76% DNA, 81,067), in accordance with the ethical and legal requirements and established best practices. The biorepositories developed and customized resources and human capacity building to support the projects. [The biorepositories developed 34 guidelines, SOPs, and documents; trained 176 clinicians and scientists in over 30 topics; sensitized ethical bodies; established MTAs and reviewed consent forms for all projects; attained import permits; and evaluated pilot exercises and provided feedback. CONCLUSIONS Biobanking in low- and middle-income countries by local skilled staff is critical to advance biobanking and genomic research and requires human capacity and resources for global partnerships. Biorepositories can help build human capacity and resources to support biobanking by partnering with researchers. Partnerships can be structured and customized to incorporate document development, ethics, training, mentorship, and pilots to prepare sites to collect, process, store, and transport biospecimens of high quality for future research.
Collapse
Affiliation(s)
- Talishiea Croxton
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria.
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA.
| | | | | | | | | | - Sharley M Aloyo
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Gideon Nsubuga
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Rogers E Kamulegeya
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Lwanga Newton
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - John Mukisa
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Mukthar Kader
- Clinical Laboratory Services, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg, South Africa
| | - Vuyo Damaneite
- Clinical Laboratory Services, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg, South Africa
| | - Sunji Nadoma
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria
| | | | | | - Emmanuel Nasinghe
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Jennifer Troyer
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Bonnie R Joubert
- National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, USA
| | - Christine Beiswanger
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA
| | - Moses L Joloba
- Integrated Biorepository of H3Africa Uganda, Kampala, Uganda
- Makerere University, Kampala, Uganda
| | - Elizabeth Mayne
- Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, National Health Laboratory Service, Johannesburg, South Africa
| | - Alash'le Abimiku
- I-HAB, Institute of Human Virology Nigeria, Abuja, Nigeria
- University of Maryland School of Medicine, Institute of Human Virology, University of Maryland Baltimore, 725 West Lombard Street Suite, Baltimore, MD, USA
| |
Collapse
|
2
|
Alarcón Garavito GA, Moniz T, Déom N, Redin F, Pichini A, Vindrola-Padros C. The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review. Eur J Hum Genet 2023; 31:282-295. [PMID: 36517584 PMCID: PMC9995480 DOI: 10.1038/s41431-022-01259-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 11/17/2022] [Accepted: 11/22/2022] [Indexed: 12/15/2022] Open
Abstract
Genomic healthcare programmes, both in a research and clinical context, have demonstrated a pivotal opportunity to prevent, diagnose, and treat rare diseases. However, implementation factors could increase overall costs and affect uptake. As well, uncertainties remain regarding effective training, guidelines and legislation. The purpose of this rapid evidence review was to draw together the available global evidence on the implementation of genomic testing programmes, particularly on population-based screening and diagnostic programmes implemented at the national level, to understand the range of factors influencing implementation. This review involved a search of terms related to genomics, implementation and health care. The search was limited to peer-reviewed articles published between 2017-2022 and found in five databases. The review included thirty articles drawing on sixteen countries. A wide range of factors was cited as critical to the successful implementation of genomics programmes. These included having policy frameworks, regulations, guidelines; clinical decision support tools; access to genetic counselling; and education and training for healthcare staff. The high costs of implementing and integrating genomics into healthcare were also often barriers to stakeholders. National genomics programmes are complex and require the generation of evidence and addressing implementation challenges. The findings from this review highlight that there is a strong emphasis on addressing genomic education and engagement among varied stakeholders, including the general public, policymakers, and governments. Articles also emphasised the development of appropriate policies and regulatory frameworks to govern genomic healthcare, with a focus on legislation that regulates the collection, storage, and sharing of personal genomic data.
Collapse
Affiliation(s)
| | - Thomas Moniz
- Rapid Research Evaluation and Appraisal Lab (RREAL), University College London, 43-45 Foley Street, W1W 7TY, London, UK
| | - Noémie Déom
- Rapid Research Evaluation and Appraisal Lab (RREAL), University College London, 43-45 Foley Street, W1W 7TY, London, UK
| | - Federico Redin
- Rapid Research Evaluation and Appraisal Lab (RREAL), University College London, 43-45 Foley Street, W1W 7TY, London, UK
| | | | - Cecilia Vindrola-Padros
- Rapid Research Evaluation and Appraisal Lab (RREAL), University College London, 43-45 Foley Street, W1W 7TY, London, UK.
| |
Collapse
|
3
|
Raghavan S. How inclusive are cell lines in preclinical engineered cancer models? Dis Model Mech 2022; 15:275571. [PMID: 35642685 PMCID: PMC9187871 DOI: 10.1242/dmm.049520] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Diverse factors contribute to significant and dire disparities in cancer risk and treatment outcomes. To address this, there was a call for inclusion of sex as a biological variable, which resulted in more instances of careful inclusion of sex in preclinical studies of cancer. Another variable in cancer treatment is genetic ancestry. Although this is considered explicitly in clinical research, it is considerably neglected in preclinical studies. Preclinical research can use several 3D in vitro model systems, such as spheroids/organoids, xenografts, or other bioengineered systems that combine biomaterials and cellular material. Ultimately, the cellular base for all of these in vitro model systems is derived from human cell lines or patient samples, to investigate mechanisms of cancer and screen novel therapeutics, all of which aim to maximize successful outcomes in clinical trials. This in itself offers an opportunity to potentiate effective treatments for many groups of people, when diverse variables like genetic ancestry are consciously included into study design. This Perspective highlights the need for conscious inclusion of genetic ancestry in preclinical cancer tissue engineering, especially when it pertains to determining therapeutic outcomes. Summary: Genetic determinants, like ancestry, impact cancer risk and therapeutic outcomes. Hence, this is an important variable to consider at the very initial stages of biomedical research at the bench.
Collapse
Affiliation(s)
- Shreya Raghavan
- Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, 5016 Emerging Technologies Building, College Station, TX 77843, USA
| |
Collapse
|
4
|
Olawoye O, Chuka-Okosa C, Akpa O, Realini T, Hauser M, Ashaye A. Eyes of Africa: The Genetics of Blindness: Study Design and Methodology. BMC Ophthalmol 2021; 21:272. [PMID: 34243759 PMCID: PMC8267233 DOI: 10.1186/s12886-021-02029-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 06/25/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND This report describes the design and methodology of the "Eyes of Africa: The Genetics of Blindness," a collaborative study funded through the Human Heredity and Health in Africa (H3Africa) program of the National Institute of Health. METHODS This is a case control study that is collecting a large well phenotyped data set among glaucoma patients and controls for a genome wide association study. (GWAS). Multiplex families segregating Mendelian forms of early-onset glaucoma will also be collected for exome sequencing. DISCUSSION A total of 4500 cases/controls have been recruited into the study at the end of the 3rd funded year of the study. All these participants have been appropriately phenotyped and blood samples have been received from these participants. Recent GWAS of POAG in African individuals demonstrated genome-wide significant association with the APBB2 locus which is an association that is unique to individuals of African ancestry. This study will add to the existing knowledge and understanding of POAG in the African population.
Collapse
Affiliation(s)
- Olusola Olawoye
- Department of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Chimdi Chuka-Okosa
- Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria
| | - Onoja Akpa
- Department of Epidemiology and Medical Statistics, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Tony Realini
- Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, USA
| | - Michael Hauser
- Department of Medicine, Duke University, NC Durham, USA
- Department of Ophthalmology, Duke University, NC Durham, USA
| | - Adeyinka Ashaye
- Department of Ophthalmology, College of Medicine, University of Ibadan, Ibadan, Nigeria
| |
Collapse
|